COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to understand whether:
1. Metformin vs fluvoxamine vs ivermectin vs metformin+fluvoxamine vs metformin+ivermectin
is superior to placebo in non-hospitalized adults with SARS-CoV-2 disease for preventing
Covid-19 disease progression.
2. To understand if the active treatment arms are superior to placebo in improving viral
load, serologic markers associated with Covid-19, and gut microbiome in non-hospitalized
adults with SARS-CoV-2 infection.
3. To understand if any of the active treatment arms prevent long-covid syndrome, PASC
(post-acute sequelae of SARS-CoV-2 infection).
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
Collaborators:
Hennepin County Medical Center, Minneapolis Northwestern University Olive View-UCLA Education & Research Institute UnitedHealth Group University of Colorado, Denver